Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 24;13:1758835920987654. doi: 10.1177/1758835920987654

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — Example of bone flare on PSMA-PET. A 61-year-old metastatic castration-resistant prostate cancer patient in treatment with enzalutamide from November 2017. Picture (A) PSMA-PET at baseline showed a right ischiatic bone metastasis Standardized Uptake Value ([SUV] = 27.3); (B) PSMA-PET at week 6 from starting enzalutamide treatment showed a rise in PSMA uptake (SUV = 43.3), but the patient had a PSA decrease >50% from baseline;. (C) PSMA-PET at week 17 presented a relevant decrease in PSMA uptake (SUV = 13).

PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; PSMA-PET, prostate-specific membrane antigen–positron emission tomography.